Tandem Diabetes Care had its Relative Strength (RS) Rating upgraded from 67 to 82 Thursday.
This unique rating tracks technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
History reveals that the best-performing stocks tend to have an RS Rating north of 80 in the early stages of their moves.
Risk Management In The Stock Market: How Much Money To Invest Now
Tandem Diabetes Care is now considered extended and out of buy range after clearing a 31.07 buy point in a first-stage cup with handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The company reported 0% earnings growth in its most recent report. Sales rose 31%.
The company earns the No. 66 rank among its peers in the Medical-Products industry group. LeMaitre Vascular, Globus Medical and Pro-Dex are among the top 5 highly rated stocks within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
